A recent study revealed that patients with hidradenitis suppurativa experience quicker treatment failure when switching to biosimilar adalimumab compared to the original.

A new report reveals the heavy personal and economic toll of MS and recommends more complete, patient focused approaches to measuring and managing the disease.

Kamuvudines are a new class of drugs that are derived from the anti-HIV nucleoside reverse transcriptase inhibitors. They are designed to inhibit the inflammasome, part of the innate immune system that is triggered in geographic atrophy.

CMS has released the negotiated prices for the second set of drugs for Medicare Part D through the Inflation Reduction Act. Discounts range from 38% for Austedo and Austedo XR to 85% for Janumet and Janumet XR.

Ralph Abraham's appointment as CDC's principal deputy director raises concerns over vaccine trust and public health amid political pressures and misinformation.

Telehealth mostly replaces in-person visits, with a 74% substitution rate, indicating lower federal costs and sustained value beyond the pandemic.

Itvisma is a one-time gene therapy approved for both children and adults with spinal muscular atrophy. It will be available in December.

A provision in the One Big Beautiful Bill delays or exempts high-spending medications with orphan indications from Medicare drug price negotiations.

A new blood test and app combination enhances tuberculosis screening in China, enabling early detection and cost-effective solutions in resource-limited areas.